Novartis India Profit Rises 16.59% to ₹32.21 Crore

Novartis India Limited has announced a standalone net profit after tax of ₹32.21 crore for the quarter ended 30 June 2026, marking a 16.59% increase compared to the same quarter last year. The company's revenue from operations for the quarter stood at ₹103.81 crore, up from ₹87.55 crore year-on-year.

The total income for the quarter reached ₹112.55 crore, a rise from ₹98.16 crore in the corresponding period of the previous fiscal year. Total expenses for the June quarter were ₹69.38 crore, compared to ₹60.94 crore year-on-year.

Profit before tax (PBT) for the quarter ended 30 June 2026 was ₹43.17 crore, up from ₹37.22 crore in the previous year's June quarter. Earnings per share (EPS) for the period increased to ₹13.05, compared to ₹11.19 a year ago.

In other news, Novartis AG entered an agreement on 19 February 2026 to sell 1,74,50,680 fully paid-up equity shares, representing 70.68% of Novartis India Limited's equity capital, to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners.

The company also assessed the impact of the four new Labour Codes notified on 21 November 2025, which resulted in an increase in the provision for employee benefits by ₹79 lakh for the year ended 31 March 2026.

Novartis India's financial performance is a significant development in the pharmaceutical industry. The company's increase in revenue and profit is a positive sign for the sector.

The increase in profit and revenue can be attributed to the company's strong performance in the quarter. The company's ability to increase its profit and revenue despite the challenges in the industry is a testament to its strength.

The pharmaceutical industry is a significant contributor to the Indian economy, and Novartis India's performance is a reflection of the industry's overall health. The company's increase in profit and revenue is a positive sign for the industry and the economy as a whole.

In conclusion, Novartis India's financial performance is a significant development in the pharmaceutical industry. The company's increase in revenue and profit is a positive sign for the sector, and its ability to navigate the challenges in the industry is a testament to its strength.

The company's performance is also a reflection of the overall health of the pharmaceutical industry in India. The industry is a significant contributor to the Indian economy, and Novartis India's performance is a positive sign for the industry and the economy as a whole.

The increase in profit and revenue is also a reflection of the company's strong management and its ability to adapt to the changing market conditions. The company's ability to increase its profit and revenue despite the challenges in the industry is a testament to its strength and its ability to navigate the complex market conditions.

Overall, Novartis India's financial performance is a significant development in the pharmaceutical industry, and its increase in revenue and profit is a positive sign for the sector. The company's ability to navigate the challenges in the industry and its strong management are a testament to its strength and its ability to adapt to the changing market conditions.